These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8886554)

  • 1. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.
    Nicolucci A; Carinci F; Graepel JG; Hohman TC; Ferris F; Lachin JM
    Diabetes Care; 1996 Oct; 19(10):1091-6. PubMed ID: 8886554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
    Boulton AJ; Levin S; Comstock J
    Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.
    Macleod AF; Boulton AJ; Owens DR; Van Rooy P; Van Gerven JM; Macrury S; Scarpello JH; Segers O; Heller SR; Van Der Veen EA
    Diabete Metab; 1992; 18(1):14-20. PubMed ID: 1563531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of treatment with an aldose-reductase inhibitor on symptomatic carpal tunnel syndrome in type 2 diabetes.
    Monge L; De Mattei M; Dani F; Sciarretta A; Carta Q
    Diabet Med; 1995 Dec; 12(12):1097-101. PubMed ID: 8750220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy.
    Tkac I; Bril V
    Diabetes Care; 1998 Oct; 21(10):1749-52. PubMed ID: 9773742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?].
    Daniele E; Coco MP
    Clin Ter; 1995 Dec; 146(12):793-99. PubMed ID: 8681499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between electroneurographic changes and serum ubiquitin levels in patients with type 2 diabetes.
    Akarsu E; Pirim I; Capoğlu I; Deniz O; Akçay G; Unüvar N
    Diabetes Care; 2001 Jan; 24(1):100-3. PubMed ID: 11194212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulse pressure is independently associated with sensorimotor peripheral neuropathy in patients with type 2 diabetes.
    Jarmuzewska EA; Mangoni AA
    J Intern Med; 2005 Jul; 258(1):38-44. PubMed ID: 15953131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients].
    Terranova R; Luca S
    Minerva Med; 1993 Sep; 84(9):461-6. PubMed ID: 8247317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
    van Gerven JM; Lemkes HH; van Dijk JG
    J Diabetes Complications; 1992; 6(1):45-8. PubMed ID: 1562758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.
    Giugliano D; Marfella R; Quatraro A; De Rosa N; Salvatore T; Cozzolino D; Ceriello A; Torella R
    Ann Intern Med; 1993 Jan; 118(1):7-11. PubMed ID: 8416161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of atrophy of foot muscles in diabetic neuropathy -- a comparative study of nerve conduction studies and ultrasonography.
    Severinsen K; Andersen H
    Clin Neurophysiol; 2007 Oct; 118(10):2172-5. PubMed ID: 17709290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve conduction velocity after combined renal-pancreatic transplantation.
    van Oosterhout EC; van Dijk JG; Gooszen HG; van der Woude FJ; Lemkes HH
    Transplant Proc; 1994 Apr; 26(2):496. PubMed ID: 8171521
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy.
    Fabiani F; De Vincentis N; Staffilano A
    Diabete Metab; 1995 Dec; 21(5):360-4. PubMed ID: 8586153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.